FrancophonIA/ELRC3.0 huggingface dataset:
English: Further dilution with either sodium chloride 9 mg/ml (0.9%) solution for injection or glucose 50 mg/ml (5%) solution for injection is required, to obtain a final concentration of between 25 and 50 micrograms/ml prior to administration to the patient.
Croatian: Za postizanje konačne koncentracije između 25 i 50 mikrograma/ml, prije davanja lijeka bolesniku potrebno je daljnje razrjeđenje s 0,9%-tnom (9 mg/ml) otopinom natrijevog klorida za injekciju ili 5 %-tnom (50 mg/ml) otopinom glukoze za injekciju.
English: Initial dose The recommended dose of topotecan is 0.75 mg/m2/day administered as a 30-minute intravenous infusion on days 1, 2 and 3.
Croatian: Početna doza Preporučena doza topotekana je 0,75 mg/m2 tjelesne površine/dan, primijenjena intravenskom infuzijom u trajanju od 30 minuta prvog, drugog i trećeg dana ciklusa.
English: Subsequent doses Topotecan should not be re-administered unless the neutrophil count is ≥ 1 x 10
Croatian: Daljnje doze Topotekan se ne smije ponovno primijeniti ukoliko broj neutrofila nije 1 x 10
English: The elimination of topotecan has only been partly investigated in man. A major route of clearance of topotecan was by hydrolysis of the lactone ring to form the ring-opened carboxylate.
Croatian: Glavni način klirensa topotekana je hidroliza laktonskog prstena i tvorba karboksilata otvorenog prstena.
English: Dosage: Renally impaired patients
Croatian: Doziranje: bolesnici s oštećenjem bubrega
English: In patients (n=39) with recurrence within 180 days after chemoradiotherapy with cisplatin, the median survival in the topotecan plus cisplatin arm was 4.6 months (95% CI:: 2.6, 6.1) versus 4.5 months (95% C.I.
Croatian: U bolesnica (n=39) s recidivom unutar 180 dana nakon kemoradioterapije s cisplatinom, medijan preživljenja u skupini liječenoj kombinacijom topotekana i cisplatina iznosio je 4,6 mjeseci (95% CI: 2,6; 6,1), u usporedbi s 4,5 mjeseca (95% CI: 2,9; 9,6) u skupini liječenoj cisplatinom, uz omjer hazarda od 1,15 (0,59; 2,23).
English: This rare side effect may affect up to 1 in 1,000 people treated with Topotecan Hospira:
Croatian: Ova rijetka nuspojava može se javiti u do 1 na 1000 osoba liječenih lijekom Topotekan Hospira:
English: How to use Topotecan Hospira
Croatian: Kako primjenjivati Topotekan Hospira
English: When topotecan (0.75 mg/m2/day for 5 consecutive days) and cisplatin (60 mg/m2/day on day 1) were administered in 13 patients with ovarian cancer, a slight increase in AUC (12%, n=9) and Cmax (23%, n=11) was noted on day 5.
Croatian: 1. dana) u 13 bolesnica s karcinomom jajnika, 5. dan je zabilježen blagi porast vrijednosti AUC-a (12%, n=9) i Cmax (23%, n=11).
English: The safety profile of topotecan when given in combination with cisplatin in the cervical cancer clinical studies is consistent with that seen with topotecan monotherapy.
Croatian: U kliničkim ispitivanjima kombinacije topotekana i cisplatina u liječenju raka vrata maternice sigurnosni profil bio je isti kao i pri monoterapiji topotekanom.
English: Each ml of concentrate contains 1 mg topotecan (as hydrochloride).
Croatian: Jedan ml koncentrata sadrži 1 mg topotekana (u obliku topotekanklorida).
English: − Pregnant staff should be excluded from working with this medicinal product.
Croatian: - Trudne radnice ne smiju rukovati ovim lijekom.
English: Signed By:
Croatian: Znakovi uključuju:
English: Handling and disposal
Croatian: Rukovanje i zbrinjavanje
English: • Itchy rash (or hives).
Croatian: • osip koji svrbi (ili koprivnjača)
English: When treating cervical cancer, Topotecan Hospira is combined with another medicine, called cisplatin.
Croatian: U liječenju raka vrata maternice, Topotekan Hospira se kombinira s drugim lijekom koji se zove cisplatin.Liječnik će odrediti odgovarajuću dozu cisplatina.
English: 9/l and a haemoglobin level of ≥ 9g/dl (after transfusion if necessary).
Croatian: 9/l i razinu hemoglobina ≥9 g/dl (nakon transfuzije ukoliko je potrebno).
English: These very common side effects may affect more than 1 in 10 people treated with Topotecan Hospira:
Croatian: Ove vrlo česte nuspojave mogu se javiti u više od 1 na 10 osoba liječenih lijekom Topotekan Hospira:
English: Anaphylactic reaction, angioedema, urticaria
Croatian: Rijetko anafilaktička reakcija, angioedem, urtikarija
English: 9/l) in 25 % of patients (8 % of courses); moderate
Croatian: 9/l) zabilježena je u 25% bolesnika (8% ciklusa), a umjerena (broj trombocita između 25,0 i 50,0 x 10
English: ≥ 100 x 10 9/l, and the haemoglobin level is ≥ 9 g/dl (after transfusion if necessary).
Croatian: 100 x 10 9/l, a razina hemoglobina  9 g/dl (nakon transfuzije, ukoliko je potrebna).
English: Each 4 ml vial of concentrate contains 4 mg topotecan (as hydrochloride).
Croatian: Jedna bočica s 4 ml koncentrata sadrži 4 mg topotekana (u obliku topotekanklorida).
English: Each 4 ml vial contains 4 mg topotecan (as hydrochloride).
Croatian: Jedna bočica s 4 ml sadrži 4 mg topotekana (u obliku topotekanklorida).
English: Mucosal inflammation
Croatian: Oštećenje bubrega
English: Rare side effects These may affect up to 1 in 1,000 people treated with Topotecan Hospira:
Croatian: Rijetke nuspojave Mogu se javiti u do 1 na 1000 osoba liječenih lijekom Topotekan Hospira:
English: Plasma clearance in patients with renal impairment (creatinine clearance 41-60 ml/min.)
Croatian: Plazmatski klirens u bolesnika s oštećenjem bubrega (klirens kreatinina 41-60 ml/min) smanjio se na približno 67% u usporedbi s kontrolnom skupinom bolesnika.
English: • Feeling sick (nausea), being sick (vomiting); diarrhoea; stomach pain; constipation.
Croatian: • mučnina, povraćanje, proljev, bolovi u trbuhu, zatvor
English: The prescribing information for cisplatin should be consulted for a full list of adverse events associated with cisplatin use.
Croatian: Za cjeloviti popis nuspojava povezanih s liječenjem cisplatinom potrebno je proučiti sažetak opisa svojstava tog lijeka.
English: These may affect more than 1 in 10 people treated with Topotecan Hospira:
Croatian: Mogu se javiti u do 1 na 10 osoba liječenih lijekom Topotekan Hospira:
English: 18.3, 31.6) compared to 13.9 weeks (95 % CI: 11.1, 18.6) for patients receiving BSC alone (p=0.0104).
Croatian: Medijan vremena preživljenja bolesnika liječenih oralnim topotekanom plus BSC-om iznosio je 25,9 tjedana (95% CI: 18,3; 31,6) u usporedbi s 13,9 tjedana (95% CI: 11,1; 18,6) u bolesnika liječenih samo BSC-om (p=0,0104).
English: Study 065
Croatian: 1050 Bruxelles
English: If dose reduction is chosen for patients who experience severe neutropenia (neutrophil count < 0.5 x 9/l) for seven days or more or severe neutropenia associated with fever or infection, or who have had treatment delayed due to neutropenia, the dose should be reduced by 0.25 mg/m 2/day to
Croatian: 9/1) koja traje sedam dana ili dulje, s teškom neutropenijom praćenom vrućicom ili infekcijom, ili u onih kojima je zbog neutropenije liječenje odgođeno, izabere smanjenje doze, istu je potrebno smanjivati po 0,25 mg/m2/dan do 1,25 mg/m2/dan (ukoliko je potrebno, moguće je daljnje smanjenje doze do
English: 9/l, a platelet count of ≥ 100 x 10 9/l and a haemoglobin level of ≥ 9 g/dl (after transfusion if necessary).
Croatian: 9/l, broj trombocita veći ili jednak 100x10 9/l i razina hemoglobina veća ili jednaka 9 g/dl (nakon transfuzije ukoliko je potrebna).
English: Oral topotecan
Croatian: Kako se primjenjuje topotekan
English: PHARMACOLOGICAL PROPERTIES
Croatian: 5 FARMAKOLOŠKA SVOJSTVA
English: Thrombocytopenia: Severe (platelets <25 x 10
Croatian: Trombocitopenija: Teška trombocitopenija (broj trombocita manji od 25,0 x 10
English: Anaemia:
Croatian: Serija:
English: Use Refer to the SmPC for full details.
Croatian: Uporaba Za sve detalje pogledajte sažetak opisa svojstava lijeka.
English: Metalyse tenecteplase
Croatian: Metalyse tenekteplaza
English: The main measure of effectiveness was the number of patients who were alive 30 days after treatment.
Croatian: Glavna mjera djelotvornosti bio je broj bolesnika koji su bili živo 30 dana nakon liječenja.
English: Around 94% of patients who received either medicine were alive 30 days after treatment.
Croatian: Otprilike 94% bolesnika koji su primili lijek bilo je živo 30 dana nakon liječenja.
English: If treatment is necessary in these patients, facilities for resuscitating them must be readily available.
Croatian: Ako je liječenje potrebno u ovih bolesnika, oprema za oživljavanje mora biti u stanju pripravnosti.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Metalyse on 23 February 2001.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje za lijek Metalyse vrijedi na prostoru Europske unije od 23. veljače 2001.
English: The full EPAR for Metalyse can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Croatian: Cjelovito Europsko javno izvješće o ocjeni dokumentacije o lijeku (EPAR) za lijek Metalyse nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Other information about Metalyse:
Croatian: Ostale informacije o lijeku Metalyse:
English: With the blood clot broken down, blood can flow more easily into the heart muscle, allowing the heart to keep working and helping to save the patient's life.
Croatian: Nakon što je krvni ugrušak razgrađen, krv može slobodnije teći u srčani mišić što omogućuje srcu nastavak rada i pomaže pri spašavanju života bolesnika.
English: Based on this and all other available data, the Committee decided that Metalyse's benefits are greater than its risks and recommended that it be given marketing authorisation.
Croatian: Na temelju ovog i svih ostalih dostupnih podataka, Povjerenstvo je odlučilo da koristi lijeka Metalyse nadmašuju s njim povezane rizike i preporučilo je izdavanje odobrenja za stavljanje lijeka u promet.
English: The CHMP noted that while Metalyse was as effective as alteplase in preventing death, it caused less serious bleeding, which meant that fewer blood transfusions were required.
Croatian: CHMP je zaključio da je lijek Metalyse, iako je bio podjednako djelotvoran kao alteplaze u sprječavanju smrti, uzrokovao manje ozbiljno krvarenje, što znači da je bilo potrebno manje transfuzija.
English: The most common bleedings (seen in between 1 and 10 patients in 100) are epistaxis (nosebleeds), gastrointestinal haemorrhage (bleeding in the stomach or gut), ecchymosis (bleeding beneath the skin), urogenital haemorrhage (bleeding from the structures that carry urine or from the genital area), bleeding at the injection site, and bleeding at puncture site.
Croatian: Najčešća krvarenja (kod 1 do 10 bolesnika na 100 bolesnika) su epistaksa (krvarenja iz nosa), gastrointestinalno krvarenje (krvarenje u želudac ili crijeva), ekimoza (krvarenje ispod kože), urogenitalno krvarenje (krvarenje iz struktura koje prenose urin ili iz genitalnog područja), krvarenje u mjestu injekcije i krvarenje u mjestu punkcije.
English: The dose to be given is adjusted according to the patient's weight (see the package leaflet).
Croatian: Doza koja se primjenjuje određuje se u skladu s tjelesnom težinom bolesnika (pogledajte uputu o lijeku).
English: This document is a summary of the European Public Assessment Report (EPAR) for Metalyse.
Croatian: Ovo je sažetak Europskoga javnog izvješća o ocjeni dokumentacije (EPAR) za lijek Metalyse.
English: It works by converting a protein in the clots called plasminogen into its active form, plasmin, which breaks down the fibrous protein holding the clot together.
Croatian: Djeluje konvertirajući protein u ugrušcima naziva plazminogen u njegov aktivan oblik, plazmin, koji razgrađuje fibrozni protein koji drži zajedno ugrušak.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Metalyse.
Croatian: Pojašnjava kako je Povjerenstvo za lijekove za primjenu kod ljudi (CHMP) ocijenilo lijek da bi donijelo mišljenje u korist izdavanja odobrenja za stavljanje lijeka u promet i svoje preporuke o uvjetima primjene lijeka Metalyse.
English: The patients were given either medicine within six hours of their symptoms appearing in addition to either aspirin or heparin.
Croatian: Bolesnici su primili lijek unutar šest sati od pojavljivanja simptoma uz dodatak aspirina ili heparina.
English: Metalyse should not be used in patients who have or have had recent bleeding problems or major surgery, or have a disease which may cause bleeding (such as a past stroke or severe high blood pressure).
Croatian: Metalyse se ne smije koristiti u bolesnika koji imaju ili su imali nedavnih problema s krvarenjem ili veći kirurški zahvat, ili imaju bolest koja može uzrokovati krvarenje (poput prethodnog moždanog udara ili ozbiljnog visokog krvnog tlaka).
English: Metalyse is given once as a single injection into a vein over around 10 seconds.
Croatian: Metalyse se primjenjuje jednom kao jedna injekcija u venu tijekom razdoblja od 10 sekundi.
English: For more information about treatment with Metalyse, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom Metalyse pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svom liječniku ili ljekarniku.
English: It is used to dissolve the blood clots that have formed inside the blood vessels supplying the heart.
Croatian: Koristi se za otapanje ugrušaka krvi koji su se formirali u krvnim žilama koje opskrbljuju srce.
English: In addition to Metalyse, the patient should also be treated with other medicines that are used to prevent blood clots such as aspirin and heparin.
Croatian: Uz lijek Metalyse, bolesnika treba također liječiti drugim lijekovima koji se koriste za sprječavanje krvnih ugrušaka poput aspirina i heparina.
English: It contains the active substance tenecteplase.
Croatian: Sadrži djelatnu tvar tenekteplazu.
English: Tenecteplase is made by a method known as ‘recombinant DNA technology': it is made by a cell that has received a gene (DNA), which makes it able to produce it.
Croatian: Tenekteplaza se proizvodi „tehnologijom rekombinantne DNK”: proizvodi se iz stanica koje su primile gene (DNK), što omogućuje proizvodnju istog.
English: Metalyse is a powder and a solvent that are made up into a solution for injection.
Croatian: Metalyse je prašak i otapalo koje se miješa u otopinu za injekciju.
English: The active substance in Metalyse, tenecteplase, is a modified copy of the human enzyme ‘tissue plasminogen activator', which the body uses to break down clots.
Croatian: Djelatna tvar lijeka Metalyse, tenekteplaza, modificirana je kopija humanog enzima „aktivatora tkivnog plazminogena”, koji tijelo koristi za razgradnju ugrušaka.
English: Treatment with Metalyse should be started as soon as possible after the start of heart attack symptoms.
Croatian: Liječenje lijekom Metalyse treba započeti što je prije moguće nakon pojavljivanja prvih simptoma infarkta miokarda.
English: What is the risk associated with Metalyse?
Croatian: Koji su rizici povezani s lijekom Metalyse?
English: The medicine can only be obtained with a prescription.
Croatian: Ovaj se lijek izdaje na liječnički recept.
English: Metalyse is used to treat adults suspected of having an acute myocardial infarction (heart attack) within six hours of the first symptoms appearing.
Croatian: Metalyse se koristi za liječenje odraslih osoba sa suspektnim infarktom miokarda (srčani napadaj) unutar šest sati od pojavljivanja prvog simptoma.
English: The most common side effect with Metalyse was haemorrhage (bleeding).
Croatian: Najčešća nuspojava lijeka Metalyse je hemoragija (krvarenje).
English: Metalyse was compared with alteplase (another medicine used to treat heart attacks) in one main study involving about 17,000 adults who were having a heart attack.
Croatian: Metalyse je uspoređen s alteplazom (drugim lijekom koji se koristi za liječenje infarkta miokarda) u jednom glavnom ispitivanju koje je obuhvatilo otprilike 17 000 odraslih osoba koje su imale infarkt miokarda.
English: Metalyse was as effective as alteplase in keeping patients alive after a heart attack.
Croatian: Metalyse je bio podjednako djelotvoran kao alteplaza u održavanju bolesnika živim nakon infarkta miokarda.
English: Metalyse should be prescribed by doctors who have experience in the use of thrombolytic treatments (treatments to dissolve blood clots).
Croatian: Metalyse mogu propisivati liječnici koji imaju iskustva u primjeni trombolitičkih lijekova (liječenja za otapanje krvnih ugrušaka).
English: Metalyse should not be used in people who have had an anaphylactic reaction (a severe, lifethreatening allergic reaction) to tenecteplase, gentamicin (an ingredient found in the medicine) or any of the other ingredients.
Croatian: Metalyse se ne smije koristiti u osoba koje imaju anafilaktičku reakciju (ozbiljnu, po život opasnu alergijsku reakciju) na tenekteplazu, gentamicin (pomoćna tvar lijeka) ili bilo koju drugu pomoćnu tvar.
English: What is Metalyse?
Croatian: Što je Metalyse?
English: Why has Metalyse been approved?
Croatian: Zašto je lijek Metalyse odobren?
English: What benefit has Metalyse shown during the studies?
Croatian: Koje su koristi lijeka Metalyse dokazane u ispitivanjima?
English: For the full list of all side effects reported with Metalyse, see the package leaflet.
Croatian: Potpuni popis nuspojava zabilježenih pri primjeni lijeka Metalyse potražite u uputi o lijeku.
English: What is Metalyse used for?
Croatian: Za što se Metalyse koristi?
English: How is Metalyse used?
Croatian: Kako se Metalyse koristi?
English: How has Metalyse been studied?
Croatian: Kako se Metalyse ispitivao?
English: How does Metalyse work?
Croatian: Kako djeluje Metalyse?
English: It is given to dogs once daily on an empty stomach at least one hour before the next meal.
Croatian: Daje se psima jednom dnevno na prazan želudac, barem sat vremena prije sljedećeg obroka.
English: This summary was last updated in November 2017.
Croatian: Sažetak je posljednji put ažuriran u studenome 2017.
English: Galliprant is a veterinary medicine.
Croatian: Galliprant je veterinarsko-medicinski proizvod.
English: The full EPAR for Galliprant can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za VMP Galliprant nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: Hands should be washed after handling the medicine.
Croatian: Nakon rukovanja proizvodom treba oprati ruke.
English: The dose is based on the bodyweight of the dog and the length of treatment depends on the response.
Croatian: Doza se utvrđuje na temelju tjelesne težine psa, a trajanje liječenja ovisi o odgovoru.
English: The most common side effect with Galliprant (which may affect more than 1 in 10 animals) is mild and generally short-lived vomiting.
Croatian: Najčešća nuspojava VMP-a Galliprant (može se javiti u više od 1 na 10 životinja) jest blago i uglavnom kratkotrajno povraćanje.
English: In total, 51% of dogs (120 of 235) were treated successfully with Galliprant at 28 days after the start of the treatment.
Croatian: Ukupno je 51 %pasa (120 od 235) bilo uspješno izliječeno VMP-om Galliprant 28 dana nakon početka liječenja, u usporedbi s 36 % pasa koji su primali placebo (82 od 231).
English: What is Galliprant and what is it used for?
Croatian: Što je Galliprant i za što se koristi?
English: This is a summary of the European public assessment report (EPAR) for Galliprant.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) VMP-a Galliprant.
English: Galliprant must not be given to pregnant, lactating or breeding dogs.
Croatian: Galliprant se ne smije davati kujama tijekom graviditeta i laktacije, kao ni rasplodnim psima.
English: The European Commission granted a marketing authorisation valid throughout the EU for Galliprant on 9 January 2018.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet VMP-a Galliprant koje je na snazi u Europskoj uniji od 09/01/2018.
English: Success was assessed by the dog owners and by veterinarians, using scoring systems for pain severity, pain interference and overall life quality.
Croatian: Uspjeh liječenja procjenjivali su vlasnici pasa i veterinari primjenjujući sustave za ocjenjivanje jačine boli, utjecaja boli na život pasa i ukupne kvalitete života.
English: Grapiprant works by blocking a specific target receptor called EP4, through which natural substances called prostaglandins act to produce pain in osteoarthritis.
Croatian: Grapiprant djeluje inhibirajući posebne ciljne receptore naziva EP4, preko kojih prirodne tvari naziva prostaglandini uzrokuju bol u slučaju osteoartritisa.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Galliprant's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Odbor za veterinarsko-medicinske proizvode (CVMP) pri Agenciji odlučio je da koristi od VMP-a Galliprant nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za primjenu u Europskoj uniji.
English: Why is Galliprant approved?
Croatian: Zašto je VMP Galliprant odobren?
English: It is not intended to provide practical advice on how to use Galliprant.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni VMP-a Galliprant.
English: Two field studies were conducted involving dogs mostly with mild to moderate osteoarthritis confirmed by radiography in at least one limb joint.
Croatian: Provedena su dva terenska ispitivanja kojima su bili obuhvaćeni psi uglavnom s blagim do umjerenim osteoartritisom u barem jednom nožnom zglobu, što je bilo potvrđeno rendgenskom snimkom.
English: If the medicine is accidentally swallowed by a person, the advice of a doctor should be sought immediately.
Croatian: U slučaju da se VMP nehotice proguta, treba odmah potražiti liječničku pomoć.
English: By blocking EP4, grapiprant helps relieve the signs of the condition.
Croatian: Inhibirajući receptore EP4 grapiprant pomaže pri ublažavanju simptoma bolesti.
English: It is used in dogs to treat pain associated with mild to moderate osteoarthritis, a condition causing swelling and pain in the joints.
Croatian: Primjenjuje se u pasa za liječenje boli povezane s blagim do umjerenim osteoartritisom, koji uzrokuje oticanje i bol u zglobovima.
English: Intermittent treatment may be beneficial in some dogs as signs of osteoarthritis come and go.
Croatian: U nekih pasa povremeno liječenje može se pokazati djelotvornim jer se simptomi osteoartritisa pojavljuju i nestaju.
English: What are the risks associated with Galliprant?
Croatian: Koji su rizici povezani s VMP-om Galliprant?
English: It contains the active substance grapiprant.
Croatian: Sadržava djelatnu tvar grapiprant.
English: Galliprant is available as tablets and can only be obtained with a prescription.
Croatian: VMP Galliprant dostupan je u obliku tableta i izdaje se samo na veterinarski recept.
English: Galliprant contains grapiprant, a non-steroidal, non-cyclooxygenase inhibiting anti-inflammatory drug (NSAID), of the piprant class, that works in a different way from other NSAIDs, which block a range of cyclo-oxygenase enzymes.
Croatian: Galliprant sadržava grapiprant, nesteroidni protuupalni lijek koji ne inhibira ciklooksigenazu (NSAID) iz razreda pripranta.
English: How is Galliprant used?
Croatian: Kako se Galliprant koristi?
English: If swallowed by a child, mild and reversible gastrointestinal signs and nausea may be seen.
Croatian: Ako ga proguta dijete, mogu se primijetiti blage i prolazne smetnje u probavnom sustavu i mučnina.
English: For the full list of side effects and restrictions with Galliprant, see the package leaflet.
Croatian: Potpuni popis nuspojava i ograničenja prilikom primjene VMP-a Galliprant potražite u uputi o VMP-u.